Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.85 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116979 | 1.00 | NPSR1 (0.85) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776238 | 0.92 | NPSR1 (0.72) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776230 | 0.92 | LMNA (0.78) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL4129393 | 0.92 | NPSR1 (1.00) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776233 | 0.90 | PTGDR2 (0.72) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776235 | 0.90 | NPSR1 (0.69) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776223 | 0.89 | LMNA (0.70) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776249 | 0.89 | NPSR1 (0.68) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL4121859 | 0.89 | NPSR1 (0.80) | NPSR1GPR55LMNAHTTMEN1 | |
| SCHEMBL13776119 | 0.89 | NPSR1 (0.80) | NPSR1GPR55LMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | NPSR1 297/4885GPR55 46/4885LMNA 4545/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | NPSR1 303/4885GPR55 38/4885LMNA 4736/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | NPSR1 297/4885GPR55 46/4885LMNA 4545/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | NPSR1 354/4885GPR55 70/4885LMNA 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.